Immune phenotype of patients with stage IV metastatic inflammatory breast cancer

Breast Cancer Research

Table 2 The median number ± standard deviation of lymphocytes per μl is indicated for 14 stage IV metastatic IBC patients and 11 healthy donors as assessed using BD Trucount™ assays

	IBC patients	Healthy donors	p values
Total lymphocytes per μl	897 ± 413	1976 ± 855	0.00018
CD3⁺ T cells per μl	646 ± 350	1496 ± 762	0.00051
CD8⁺ T cells per μl	222 ± 117	458 ± 215	0.015
CD4⁺ T cells per μl	372 ± 236	873 ± 701	0.00093
CD4⁺CD8⁺ cells per μl	6 ± 5	14 ± 104	0.0030
NK cells per μl	117 ± 80	296 ± 142	0.00076
B cells per μl	137 ± 101	223 ± 96	0.017
CD4/CD8 ratio	1.7 ± 0.7	2.6 ± 1.6	0.023
CD4⁺ central memory cells per μl	165 ± 88	335 ± 296	0.00051
CD4⁺ effector cells per μl	1 ± 29	12 ± 13	0.0034
CD4⁺ effector memory cells per μl	68 ± 39	136 ± 91	0.0016
CD4⁺ naïve cells per μl	125 ± 126	382 ± 330	0.00093
CD8⁺ central memory cells per μl	20 ± 32	49 ± 32	0.0048
CD8⁺ effector cells per μl	43 ± 39	87 ± 56	0.37
CD8⁺ effector memory cells per μl	46 ± 54	112 ± 77	0.035
CD8⁺ naïve cells per μl	89 ± 68	168 ± 131	0.052
CD16 GMFI on CD56^bright NK cells	4896 ± 3883	3224 ± 1361	0.023
Granzyme B GMFI on CD56^bright NK cells	1257 ± 1064	578 ± 474	0.049
Perforin GMFI on CD56^bright NK cells	9412 ± 18,059	4564 ± 4717	0.049

All comparisons with significant p values < 0.05 also passed false discovery rate testing

ISSN: 1465-542X